ALLO
Closed
Allogene Therapeutics Inc
1.18
+0.05 (+4.42%)
Last Update: 01 Jul 2025 23:14:00
Yesterday: 1.13
Day's Range: 1.11 - 1.23
Send
sign up or login to leave a comment!
When Written:
4.94
Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative allogeneic CAR T and NK cell therapies for the treatment of cancer. The company was founded in 2018 and is headquartered in South San Francisco, California.
Allogene's technology platform is based on the use of healthy donor cells, which are genetically modified to express chimeric antigen receptors (CARs) or natural killer (NK) cell receptors that can recognize and attack cancer cells. These allogeneic cell therapies have the potential to provide a more scalable and cost-effective approach to cancer treatment compared to autologous cell therapies, which require the patient's own cells to be harvested and engineered.
Allogene's lead product candidate, ALLO-501, is an allogeneic CAR T therapy targeting CD19-positive B-cell malignancies. The company is also developing several other CAR T and NK cell therapies for the treatment of various types of cancer.
Allogene went public in October 2018 and is traded on the NASDAQ under the ticker symbol ALLO. The company has partnerships with several pharmaceutical companies, including Pfizer, Servier, and Cellectis.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Allogene's technology platform is based on the use of healthy donor cells, which are genetically modified to express chimeric antigen receptors (CARs) or natural killer (NK) cell receptors that can recognize and attack cancer cells. These allogeneic cell therapies have the potential to provide a more scalable and cost-effective approach to cancer treatment compared to autologous cell therapies, which require the patient's own cells to be harvested and engineered.
Allogene's lead product candidate, ALLO-501, is an allogeneic CAR T therapy targeting CD19-positive B-cell malignancies. The company is also developing several other CAR T and NK cell therapies for the treatment of various types of cancer.
Allogene went public in October 2018 and is traded on the NASDAQ under the ticker symbol ALLO. The company has partnerships with several pharmaceutical companies, including Pfizer, Servier, and Cellectis.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!